News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s $2.6 Billion Bid for Human Genome Sciences, Inc. (HGSI) Goes Hostile


5/9/2012 6:43:59 AM

GlaxoSmithKline will take its $2.6 billion bid for Human Genome Sciences direct to shareholders this week, after its takeover offer was rejected last month by the U.S. biotech group's board. The decision to go hostile with the $13 a share cash tender offer sets GSK up for a potentially lengthy battle with those Human Genome investors who believe it is not offering enough. "They will do fantastically well out of this - at $13 it is a steal," said Mark Evans, a fund manager at Taube Hodson Stonex, the sixth largest investor in Human Genome with a 5.6 percent stake.

Read at Reuters
Read at Philadelphia Inquirer
Read at SF Gate
Read at Washington Post
Read at Fox News
Read at New York Times

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES